Font Size, 'Look-Alikes' And Costs Are Top Concerns In Australian Drug Labeling Review
This article was originally published in SRA
Executive Summary
As part of a drive to get pharmaceutical companies to put clearer and more comprehensive information on their drug labels, Australia's regulatory body, the Therapeutic Goods Administration, is asking stakeholders to comment on its newly updated labeling rules, which among other things would impose a minimum font size for active substance names and require more substances to be listed on the label1.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.